Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2003
05/15/2003WO2003039556A1 Rehydrating formulation
05/15/2003WO2003039555A2 Agents for treating lesions of the nervous system
05/15/2003WO2003039554A1 Enantiomers of steroids for the enhancement of memory and cognitive function
05/15/2003WO2003039553A1 Compositions for treatment of postmenopausal female sexual dysfunction
05/15/2003WO2003039552A1 Combination of pde4 or pde3/4 inhibitor and an anti-rheumatic drug
05/15/2003WO2003039551A1 Combination therapy comprising zd6474 and a taxane
05/15/2003WO2003039550A1 Use of tyrosine kinase inhibitors for whitening human skin and treating melanocyte dysfunction associated diseases
05/15/2003WO2003039549A2 Selective antibacterial agents
05/15/2003WO2003039548A1 Hydrazono-malonitriles
05/15/2003WO2003039547A1 Use of sulfonamide derivatives in the treatment of obesity or for the reduction of food intake
05/15/2003WO2003039546A1 New uses for anti-malarial therapeutic agents
05/15/2003WO2003039545A2 Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers
05/15/2003WO2003039544A1 Naphtyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
05/15/2003WO2003039543A1 Derivatives of phenoxy-n-'4-(isothiazolidin-1,1-dioxid-2yl)pheny!-valerian- acid amide and other compounds as inhibitors of the coagulation factor xa in the treatment of thromboembolic diseases and tumors
05/15/2003WO2003039542A1 Combination therapy for treating alzheimer's disease
05/15/2003WO2003039541A1 4-[3,5-bis-(2-hydroxy-phenyl)-[1,2,4]triazol-1-yl]-benzoic acid derivatives for treating an excess of metal in the body
05/15/2003WO2003039540A2 D-amino acid oxidase inhibitors for learning and memory
05/15/2003WO2003039539A2 Use of endothelin receptor antagonists in the treatment of tumour diseases
05/15/2003WO2003039538A1 Composition containing a flavonoid glycone and method for using same as anti-proliferative
05/15/2003WO2003039537A1 Chemoprotectant compositions
05/15/2003WO2003039536A1 Enhancement of taxane-based chemotherapy by a cdk1 antagonist
05/15/2003WO2003039535A1 Method and composition for preventing or reducing the symptoms of insulin resistance syndrome
05/15/2003WO2003039534A1 Compositions and methods for treating osteoporosis
05/15/2003WO2003039533A1 Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
05/15/2003WO2003039532A1 Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid
05/15/2003WO2003039531A1 Modified release tamsulosin tablets
05/15/2003WO2003039530A1 Tamsulosin tablets
05/15/2003WO2003039529A1 Selective antibacterial agents
05/15/2003WO2003039528A1 Pharmaceutical composition comprising an adenosine a1/a2 agonist and a sodium hydrogen exchanger inhibitor
05/15/2003WO2003039527A1 Controlled release tablets of metformin
05/15/2003WO2003039526A1 Treatment of breast cancer
05/15/2003WO2003039525A1 Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
05/15/2003WO2003039524A1 Anti-muscarinic agent and estrogen-agonist for treating unstable or overactive bladder
05/15/2003WO2003039521A1 Solid, stabilized, prompt- and/or modified-release therapeutical systems for the oral administration of liquid active principles, excipients or foodstuffs
05/15/2003WO2003039519A2 Dual controlled release dosage form
05/15/2003WO2003039518A1 Oral controlled release forms useful for reducing or preventing nicotine cravings
05/15/2003WO2003039517A1 Process for preparing quick dissolving, high loading ribavirin compositions
05/15/2003WO2003039516A1 Method for improving dissolution of poorly dispersible medicaments
05/15/2003WO2003039513A1 Method for the formation of ibuprofen crystals
05/15/2003WO2003039512A1 Liposomal formulations and related methods
05/15/2003WO2003039511A1 New use of ethoxylated phytosterols and phytostanols
05/15/2003WO2003039510A1 Compositions containing oils having a specific gravity higher than the specific gravity of water
05/15/2003WO2003039509A1 Use of oligosaccharides in cosmetic or dermatological compositions for stimulating adherence of keratinocytes on the dermoepidermal junction major proteins and restoring epidermal cohesion
05/15/2003WO2003039507A1 Cosmetic and dermatological anti-uv formulations containing hydroxybenzophenone and triazine and/or benzotriazol derivatives
05/15/2003WO2003039488A2 A method for treating inflammatory bowel disease
05/15/2003WO2003039480A2 Method of treating disorder related to high cholesterol concentration
05/15/2003WO2003039479A2 Polymeric thiol-linked prodrugs
05/15/2003WO2003039477A2 Generation of virus-like particles and demonstration of lipid rafts as sites of filovirus entry and budding
05/15/2003WO2003039476A2 Methods and compositions for treating hematological disorders using 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874
05/15/2003WO2003039475A2 Methods of identifying and using modulators of fractalkine receptor
05/15/2003WO2003039473A2 Method for treating or preventing inflammatory diseases
05/15/2003WO2003039472A2 Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process
05/15/2003WO2003039469A2 Heteroaryl derivatives as superior ligands for nociceptin receptor orl-1
05/15/2003WO2003039468A2 Antimnemonic therapy for hypermemory syndromes
05/15/2003WO2003039466A2 Method of treating estrogen responsive breast cancer
05/15/2003WO2003039465A2 Treating canker sores with patches to speed healing and relieve pain
05/15/2003WO2003039464A2 Antimuscarinic aerosol
05/15/2003WO2003039462A2 B-cell lymphoma specific antigen for use in diagnosis and treatment of b-cell malignancies
05/15/2003WO2003039460A2 Mitotic kinesin inhibitors
05/15/2003WO2003039457A2 Anti-mycobacterial compounds
05/15/2003WO2003039455A2 Methods of treating endometreosis
05/15/2003WO2003039453A2 Novel benzoyl peroxide compositions for the treatment of dermatological disorders and methods for their use
05/15/2003WO2003039452A2 Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
05/15/2003WO2003039451A2 Thiazole pyridazinones as adenosine antagonists
05/15/2003WO2003039450A2 Improvements in or relating to inhibition of viruses
05/15/2003WO2003039449A2 Modulation of dopaminergic neurons
05/15/2003WO2003039446A2 Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible no-synthase
05/15/2003WO2003039440A2 Substituted 4-phenyl-4-(1h-imidazol-2-yl)-piperidine derivatives for reducing ischaemic damage
05/15/2003WO2003039439A2 Deuterated pyrazolopyrimidinones and drugs containing said compounds
05/15/2003WO2003039437A2 Orally administered pharmaceutical preparation comprising liposomically encapsulated paclitaxel
05/15/2003WO2003039436A2 Pharmaceutical compositions containing oxybutynin
05/15/2003WO2003039435A2 Process of obtaining colloidal dispersions of amphotercin b; compounds based on amphothericine b for enteral, paraenteral and topical use; use of these compounds in the treatment of systemic mycoses and parasitic infections
05/15/2003WO2003039418A1 Compositions for the treatment of infectious diseases
05/15/2003WO2003039404A2 Methods for treating ocular neovascular diseases
05/15/2003WO2003039352A2 Methods of reversing and preventing cardiovascular pathologies
05/15/2003WO2003039342A2 Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145
05/15/2003WO2003039258A1 Pesticidal and parasitical di-and trifluorosubstituted alkene compounds
05/15/2003WO2003039231A2 Compounds and methods for treating transplant rejection
05/15/2003WO2003009837A3 Treatment of vascular events in diabetics using lipid-modifying compositions
05/15/2003WO2003006063A3 Formulation comprising fulvestrant
05/15/2003WO2003004509A3 C12 modified erythromycin macrolides and ketolides having antibacterial activity
05/15/2003WO2003000692A3 Oxytocin agonists
05/15/2003WO2002102169A3 Synthetic fat composition
05/15/2003WO2002100836A3 Compounds, compositions and methods for modulating beta-amyloid production
05/15/2003WO2002100342A3 (s, s'), (s, r')-amphetaminil, compositions and uses thereof
05/15/2003WO2002098853A3 Inhibitors of cell proliferation, angiogenesis, fertility, and muscle contraction
05/15/2003WO2002085303A3 Substituted tetracycline compounds for the treatment of malaria
05/15/2003WO2002083926A3 Methods of diagnosing and treating small intestinal bacterial overgrowth (sibo) and sibo-related conditions
05/15/2003WO2002072025A3 Improving postsynaptic response by a combination of 4-minopyridine and agonist
05/15/2003WO2002069976A3 Use of ovarian hormone for increasing neural stem cell number
05/15/2003WO2002068056A3 Combination comprising a 1,4-dioxonaphathalene compound and ribenoside
05/15/2003WO2002067961A3 Therapeutic uses of herbal compositions
05/15/2003WO2002064046A3 A compound and method of treatment for fungal pathologies of the oral cavity
05/15/2003WO2002058730A3 Compositions for treatment of ocular neovascularization
05/15/2003WO2002058679A3 Antiangiogenic compounds and an assay for inhibitors of cell invasion
05/15/2003WO2002057298A3 C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases
05/15/2003WO2002056027A3 Regulation of neutral development by daedalos
05/15/2003WO2002055108A9 Targeted modification of intracellular compounds
05/15/2003WO2002049620A3 Induced phase transition method for the production of microparticles containing hydrophobic active agents
05/15/2003WO2002047672A3 Treatment of cystic fibrosis with alkalinizing agents
1 ... 5466 5467 5468 5469 5470 5471 5472 5473 5474 5475 5476 5477 5478 5479 5480 5481 5482 5483 5484 5485 5486 ... 7860